Evidence map›Paper›PMID 37018659›Full record

ArticleBlood2023

Mechanosensing via a GpIIb/Src/14-3-3ζ axis critically regulates platelet migration in vascular inflammation.

Rainer Kaiser, Afra Anjum, Lisa Kammerer, Quentin Loew, Anastassia Akhalkatsi, Dario Rossaro, Raphael Escaig, Augustin Droste Zu Senden, Ben Raude, Michael Lorenz and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Platelet effector functions in inflammation.Research and practice in thrombosis and haemostasis · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. GRespiratory research · 2024
    Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Rainer KaiserMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0003-1750-3395
Afra AnjumMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0002-1976-4102
Lisa KammererMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Quentin LoewMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Anastassia AkhalkatsiMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Dario RossaroMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Raphael EscaigMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Augustin Droste Zu SendenMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Ben RaudeDepartment of Vascular Surgery, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Michael LorenzMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Christoph GoldMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Kami PekayvazMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0003-4040-650X
Thomas BrockerInstitute for Immunology, Biomedical Center, Medical Faculty, Ludwig-Maximilian University Munich, Munich, Germany.
Jan KranichInstitute for Immunology, Biomedical Center, Medical Faculty, Ludwig-Maximilian University Munich, Munich, Germany.ORCID 0000-0002-9928-4132
Julian Walter HolchDepartment of Medicine III, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.ORCID 0000-0002-5139-4957
Steffen MassbergMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.
Florian GaertnerMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0001-6120-3723
Leo NicolaiMedizinische Klinik und Poliklinik I, University Hospital Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0003-0776-5885
LMU Klinikum · DEHumboldt-Universität zu Berlin · DEUrologische Klinik München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets are not only the first responders in thrombosis and hemostasis but also central players in inflammation. Compared with platelets recruited to thrombi, immune-responsive platelets use distinct effector functions including actin-related protein complex 2/3-dependent migration along adhesive substrate gradients (haptotaxis), which prevents inflammatory bleeding and contributes to host defense. How platelet migration in this context is regulated on a cellular level is incompletely understood. Here, we use time-resolved morphodynamic profiling of individual platelets to show that migration, in contrast to clot retraction, requires anisotropic myosin IIa-activity at the platelet rear which is preceded by polarized actin polymerization at the front to initiate and maintain migration. Integrin GPIIb-dependent outside-in signaling via Gα13 coordinates polarization of migrating platelets to trigger tyrosine kinase c-Src/14-3-3ζ-dependent lamellipodium formation and functions independent of soluble agonists or chemotactic signals. Inhibitors of this signaling cascade, including the clinically used ABL/c-Src inhibitor dasatinib, interfere predominantly with the migratory capacity of platelets, without major impairment of classical platelet functions. In murine inflammation models, this translates to reduced migration of platelets visualized by 4D intravital microscopy, resulting in increased inflammation-associated hemorrhage in acute lung injury. Finally, platelets isolated from patients with leukemia treated with dasatinib who are prone to clinically relevant hemorrhage exhibit prominent migration defects, whereas other platelet functions are only partially affected. In summary, we define a distinct signaling pathway essential for migration and provide novel mechanistic insights explaining dasatinib-related platelet dysfunction and bleeding.

Indexed as

Blood PlateletsThrombosis14-3-3 ProteinsActinsAnimalsDasatinibHumansInflammationMicePlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Membrane Glycoprotein IIb14-3-3 ProteinsActinsDasatinibPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Membrane Glycoprotein IIb

Identifiers

PMID37018659
PMCPMC10646815
OpenAlexW4362638384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.